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Patients diagnosed with non-clear renal cell carcinoma have often been excluded from 
clinical trials due to the shortage of treatments available, the low incidence of tumours with 
non-clear histology, and the corresponding diversity of intrinsic molecular features. This 
approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with 
non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor 
inhibitor, has been recently investigated in patients  with non-clear cell histologies of renal 
cell cancer. In this review, we have summarized available data on the use of cabozantinib 
in non-clear renal cell carcinoma. 
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Cabozantinib is a potent inhibitor of multiple receptor tyrosine kinases involved in 
carcinogenesis, angiogenesis, tumour growth and metastasis. The main targets of 
cabozantinib are vascular endothelial growth factor receptor 2 (VEGFR 2) and MET, and 
other targets include VEGFR 1 and 3, KIT, AXL and FLT3 [1] (Figure 1). Two large phase 
III trials have assessed the efficacy and safety profile of cabozantinib in patients affected by 
clear cell renal cell cancer (CCRCC). The CABOSUN trial [2] compared cabozantinib to 
sunitinib as first-line therapy and the METEOR trial [3] compared cabozantinib to everolimus 
in patients who had a progression of disease following an anti-VEGFR targeted therapy. 
Based on the results of CABOSUN and METEOR trials, and the encouraging results from 
two small retrospective studies [4,5], plus the lack of treatment available for non-clear cell 
renal cell carcinoma (NCCRCC), it has been speculated that cabozantinib is a valid option 
for NCCRCC which accounts for 10 to 20% of all renal cell carcinomas (RCC) [6]. Indeed, 
cabozantinib was recently demonstrated to be effective in patients diagnosed with renal cell 
carcinoma with non-clear cell histologies (NCCRCC) [7]. In this mini-review, we have 
summarized available data on the use of cabozantinib in NCCRCC. 
Molecular characteristics of NCCRCC 
NCCRCC treatment continues to be controversial due to its genetic features, variable 
prognosis as well as clinical and morphological characteristics [8,9] (Table 1). Currently, a 
set of inherited syndromes predispose to histological subtypes of renal cancer such as Von 
Hippel-Lindau (VHL) syndrome (correlated with specific mutations in the VHL gene and clear 
cell RCC histology), hereditary leiomyoma renal cell carcinoma (RCC) (correlated with 
mutations in the fumarate hydratase gene and papillary RCC type II), hereditary papillary 
RCC (correlated with mutations in c-MET and papillary RCC type I) and Birt-Hogg-Dubé 
 
syndrome (BHD; correlated with alterations in the BHD gene and chromophobe RCC) 
[10][11]. It is well established that genetic or epigenetic alterations in the VHL tumour 
suppressor gene on chromosome 3p25.3 account for nearly 90% of sporadic clear cell RCC 
tumours [12,13], but this is not common in NCCRCC where only 16% of sporadic cases 
have been reported with alterations in VHL [14]. Despite the rarity of VHL alteration in 
NCCRCC, differences in the expression pattern for VEGF and mRNA levels of its receptors 
(VEGFR 1-2) between papillary and clear cell RCC (cRCC) have been reported, with higher 
levels for tumours with CCRCC histology, potentially explaining the differences in the 
pathways associated with angiogenesis [15]. In addition, it has been shown that 
chromophobe and papillary histologies account for around 80% of NCCRCC [8,9]. In 
chromophobe RCCs, the mammalian target of rapamycin (mTOR) and consequently the 
tumour suppressor protein 53 (TP53), are the commonest pathways implicated in 
oncogenesis [16–18]. A range of mTOR pathway molecular components such as PTEN, 
pAkt, p27 and pS6 have been shown to be overexpressed (compared to normal kidney 
tissue) and permanently activated in CCRCC as well as NCCRCC [19,20]. Solid staining for 
CD117 (cKIT) plus a CD117 cytoplasmic reactivity for chromophobe RCC has been reported 
in several studies [21,22]. In contrast, papillary RCCs include type 1, which is considered 
sporadic and related to MET mutations or alternatively epidermal growth factor receptor 
(EGFR) mutations [23]; both genes are involved in proliferation, cell survival, angiogenesis 
and motility. Type 2 papillary RCC is usually more aggressive, frequently hereditary and 
related to mutations in the fumarate hydratase (FH), CDKN2A and SETD2 genes and to 
fusions involving the TFE3 gene [16,24]. Lastly, collecting ductal carcinoma (CDC), which 
generates from the renal collecting ducts, is characterized by a very rare and aggressive 
phenotype with a high rate of tumour infiltrating lymphocytes (TILs) [25]. In the past, different 
research groups investigated RCC gene expression profile with DNA microarrays, reporting 
 
unique expression profiles for different RCC histological subtypes as well as suggesting that 
each subtype is driven by different tumorigenic pathways such as the overexpression of 
GST-α, IGFBP-3 and VEGF for CCRCC and the overexpression of cytokeratin 7 (CK7) and 
CD117 for the papillary and chromophobe NCCRCCs respectively [26–28]. These data have 
been recently confirmed by different groups employing next generation sequencing (NGS) 
[7,29]. Differentially expressed genes might be used as specific diagnostic and prognostic 
markers and lead to novel targeted therapeutic strategies [30]. 
Clinical efficacy  
The rarity of NCCRCC  means that available therapies are still inferred from clinical evidence 
for metastatic clear cell RCC, and only a small number of prospective randomised trials have 
been performed so far. Retrospective analysis by the International Metastatic RCC 
Database Consortium (IMDC) in 2013 [31] revealed a worse survival outcome for patients 
with metastatic NCCRCC (mOS of 12.8 months) compared to patients diagnosed with clear 
cell RCC (mOS of 22.3 months) (P<0.001). Although the chromophobe NCCRCC histotype 
showed a survival outcome similar to clear cell RCCs, the sarcomatoid subgroup of 
chromophobe NCCRCCs showed a poorer survival outcome [32].  
In 2016, the prospective phase II randomised trials ESPN and ASPEN compared the 
efficacy of everolimus, an mTOR inhibitor, with sunitinib, a multiple receptor tyrosine kinase 
inhibitor (TKI). Both studies reported an improvement in terms of progression-free survival 
(PFS) for patients administered with sunitinib as first-line regimen, but not a clear benefit in 
terms of overall survival (OS) [33,34]. In the ESPN trial, 68 patients diagnosed with papillary 
(27), chromophobe (12), not classified (10), translocation (7) and sarcomatoid (12) 
metastatic NCCRCC were randomized to receive oral everolimus (10 mg/day) or oral 
sunitinib (50 mg/day) for 4 weeks plus 2 weeks off with crossover at disease progression. In 
 
the ESPN trial, the median PFS (mPFS) was 4.1 months with everolimus and 6.1 months 
with sunitinib (p=0.6); the median OS (mOS) for everolimus was 10.5 months but not 
reached for sunitinib (p=0.014). Ultimately, mOS was 14.9 and 16.2 months with everolimus 
and sunitinib, respectively (p=0.18) [34]. Grade 3 or 4 adverse events (AE) occurred in 88% 
and 54% of patients who received sunitinib and everolimus, respectively; fatigue was the 
most common event (36%) followed by neutropenia (27%), diarrhoea (21%), hypertension 
(18%), and hyponatremia (15%). In the ASPEN trial, 108 patients diagnosed with metastatic 
papillary, chromophobe or unclassified NCCRCC, with no previous systemic therapy, were 
randomly assigned (1:1) to receive either 10 mg/day everolimus (57 patients) or 50 mg/day 
sunitinib (51 patients) orally on days 1 through 28 of each 42-day cycle. Sunitinib improved 
PFS compared to everolimus (8.3 months [80% CI 5.8-11.4] vs 5.6 months [5.5-6.0] hazard 
ratio 1.4 [80% CI 1.03-1.92] p=0.16), even though heterogeneity was observed based on 
the prognostic risk groups and histological subtypes. The OS was similar between the two 
groups under evaluation (hazard ratio 1.2 [95% CI 0.7-2.1]) and within the subsets of 
patients (risk group, histology). The most common grade 3 and 4 AE observed were 
hypertension (24% and 2%), infection (12% and 7%) in the sunitinib and everolimus groups, 
respectively [33].  
Recently, among a cohort of 1922 patients in the Korean metastatic RCC registry, a 
retrospective study analysed 156 (8.1%) patients diagnosed with papillary (93), 
chromophobe (20), collecting duct (18), unclassified (16) and Xp11.2 translocation (9) 
metastatic NCCRCC. Patients with metastatic NCCRCC were all pre-treated with mTOR 
inhibitor, cytokines or VEGF-tyrosine kinase inhibitors [VEGF-TKIs], and reported a worse 
total PFS (median: 6.0 vs 12.0 months, P = 0.0002), first-line PFS (median: 5.0 vs 8.0 
months, P = 0.0008) and cancer-specific survival (CSS) (median: 24.0 vs 31.0 months, P = 
0.0272) when compared to the patient group with metastatic clear cell RCC [35]. 
 
Additionally, the study reported a better survival outcome in terms of total PFS (14.0 vs 24.0 
vs 12.0 months), first-line PFS (10.0 vs 18.0 vs 8.0 months) and CSS (58.0 vs 31.0 vs 31.0 
months) in the chromophobe, Xp11.2 translocation and clear cell groups, respectively [35]. 
In contrast, patient groups with papillary, collecting duct and unclassified histology reported 
poorer survival outcomes than those in the clear cell histology group with a total PFS of 6.0 
vs 4.0 vs 4.0 vs 12.0 months, respectively, a first-line PFS of 4.0 vs 4.0 vs 4.0 vs 8.0 months, 
respectively, and a CSS of 19.0 vs 35.0 vs 10.0 vs 31.0 months, respectively [35]. 
An American multicentre retrospective study recruited 23 patients diagnosed with metastatic 
NCCRCC (48% histology subtypes were not classified, 44% were papillary), previously 
treated with sunitinib (65%), pazopanib (30%) or axitinib (17%) and administered with the 
anti-PD1 monoclonal antibody nivolumab following disease progression between 12/2015 
and 01/2017 [36]. This study demonstrated the safety and efficacy of nivolumab in NCCRCC 
treatment. Even though the median PFS was 4.2 months and median OS outcome was not 
reached after 6.5 months of median follow up, among 21 assessable patients, 6 (29%) 
reported partial response (PR) and 4 (19%) reported stable disease (SD) after radiologic 
evaluation with a 5.1 months median time to best response [36]; there were no treatment-
related deaths. The commonest AE reported were fever (13%) and fatigue (13%) and the 
commonest grade 3 or 4 AE were fever (7%) and rash (5%). Nivolumab and cabozantinib 
were both approved as a second-line regimen for RCC. Nivolumab has more recently been 
shown to moderately improve the outcome in NCCRCC patients in a recent meta-analysis 
[37] and cabozantinib showed a significant improvement in PFS when compared to 
nivolumab in a systematic review, even though no difference in OS was reported [38]. In the 
absence of head-to-head comparison between nivolumab and cabozantinib, however, it 
remains challenging to identify the better approach for NCCRCC patients. 
 
An interesting result was reported by another American retrospective study where 30 
metastatic NCCRCC patients with different histology (17 papillary, 6 chromophobes, 3 
unclassified, 2 bearing genetic translocation and 2 sarcomatoid) were administered with 60 
mg daily cabozantinib. According to the final report, of the 28 patients with measurable 
disease, 18 (64%) reported stable disease (SD), 4 (14%) reported partial response (PR) (2 
papillary, 1 chromophobe and 1 not classified RCC), 6 (21%) reported progression of 
disease, accounting for a disease control rate of 78% and an objective response rate of 
14%. After a median follow-up of 20.6 months (95% confidence interval [CI]: 11.4-28.8), the 
median PFS was 8.6 months (95% CI: 6.1-14.7) and median OS was 25.4 months (95% CI: 
15.5-35.4) [5]. Of note, 12 patients (57%) required dose reduction due to drug toxicity with 
fatigue (63%), diarrhoea (57%) and hand-foot skin reaction (37%) as the main AE.  
Cabozantinib has also been recently investigated in a retrospective, cohort clinical trial 
carried out in 22 centres with 122 patients enrolled with non-clear cell histology confirmed 
diagnosis [7]. The vast majority of patients showed papillary histology (59%), followed by 
Xp11.2 translocation (15%), unclassified histology (13%), chromophobe histology (9%) and 
collecting duct histology (4%). All patients were previously treated between 2015 and 2018 
with any line of therapy available. According to RECIST criteria, radiological complete or 
partial positive response to the treatment was reported by 30 (27%) patients. With a median 
of 11 months follow-up, patients reported 12.0 months mOS and 7.0 months mPFS. 
Cabozantinib discontinuation occurred mostly due to progression of disease (85%) and drug 
toxicity (7%), leading to a median time to treatment failure (TTF) of 6.7 months. 101 patients 
(83%) were daily administered with cabozantinib (60 mg) with fatigue (52%), diarrhoea 
(34%), rash and palmar-plantar erythrodysesthesia (31%), nausea (29%) and hypertension 
(28%) reported as primary side effects. These side effects were mild to moderate grade, 
evaluated as acceptable and manageable with no severe clinical implication and in line with 
 
common tyrosine kinase inhibitor (TKI) side effects. 58 patients (48%) were investigated 
with next generation sequencing (NGS): cyclin-dependent kinase inhibitor 2A (CDKN2A) 
was the commonest mutated gene (22% of cases) among all tumours, followed by 
mesenchymal-epithelial transitions (MET) (20%). According to the authors and considering 
that 29 patients (24%) were previously administered with three or more chemotherapy 
regimens, cabozantinib showed promising efficacy and tolerable toxicity profile in the 
treatment of naïve and heavily pre-treated NCCRCC patients.  
Among potential shortcomings of this study, patient recruitment (i.e. heterogeneous 
histology), clinical background and the retrospective nature of the study represent possible 
biases. In addition, not every patient was evaluated for cabozantinib efficacy in relation to 
genomic mutations and not every patient was centrally reviewed for objective response. 
Although several studies have included MET biomarkers for the identification of patients 
who might benefit most from HGF/MET single or combined targeted therapies, reliable data 
on the predictive role of MET aberrations as response markers are lacking [39]. Also, time-
to-treatment failure (TTF) endpoint has been reported instead of PFS. This could have led 
to consideration of treatment discontinuation due to a physician's decisions on drug toxicity 
rather than documented tumour progression. Lastly, recent real-world data (RWD) analysis 
of cabozantinib reported PFS data for pre-treated patients with metastatic RCC. It is 
noteworthy that the PFS of cabozantinib as a second-line and third-line regimen was 7.76 
and 11.38 months respectively, with no significant differences between clear cell and non-
clear cell histology. This is potentially explained by the higher prevalence of papillary 
histology tumours in the NCCRCC group [40]. In order to avoid toxicity and unwanted drug 
discontinuation, liquid chromatography-tandem mass spectrometry could be used to assess 
cabozantinib in plasma and monitor the exposure levels of patients [41]. 
 
Ongoing trials 
Currently, cabozantinib is under evaluation in four phase II clinical trials, all in a “recruiting” 
status with no preliminary results available (Table 2). The NCT03685448 (UNICAB) trial is 
investigating the effectiveness in terms of objective response rate (ORR), safety and 
tolerability of 60 mg/day cabozantinib alone (single arm) in 48 patients diagnosed with locally 
advanced or metastatic NCCRCC who progressed after prior therapy. In the NCT03635892 
trial, 57 patients with advanced or metastatic NCCRCC and no prior PD-1/PD-L1 therapy 
have been administered with 40 mg/day cabozantinib plus 420 mg nivolumab at day 1 and 
day 15 per cycle. The primary outcome of the study is the assessment of ORR defined by 
histology across three different cohorts. 84 patients with NCCRCC are expected to be 
enrolled in the NCT03541902 clinical trial and randomized to receive daily oral cabozantinib 
or sunitinib malate on days 1-28; PFS within the two cohorts is the primary outcome. Lastly, 
the NCT03354884 trial (BONSAI) is recruiting 23 patients with collecting duct non-clear cell 
histology to be orally administered with 60 mg/day cabozantinib in a single arm to define the 
ORR of cabozantinib. Eligible patients must be affected by unresectable, advanced or 
metastatic collecting duct NCCRCC, with no prior treatment. 
 
In summary, while RCC with clear cell histology has been largely investigated with positive 
results, NCCRCC has been poorly investigated so far due to the shortage of samples 
available and the genetic, clinical and prognostic heterogeneity. Nevertheless, given the 
questionable results from studies to date, and uncertainty as to whether NCCRCC patients 
can be administered with cabozantinib, we would emphasize the need to optimize NCCRCC 
therapies in the foreseeable future. Given this background, the noteworthy effort made in 
clinical studies to date could pave the way to new approaches to NCCRCC treatment. An 
 
approach involving a prospective histology- and molecular biology-driven umbrella trial for 
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